Compare LI & HOLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LI | HOLX |
|---|---|---|
| Founded | 2015 | 1985 |
| Country | China | United States |
| Employees | 30728 | N/A |
| Industry | Auto Manufacturing | Medical Electronics |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.1B | 16.9B |
| IPO Year | N/A | 1995 |
| Metric | LI | HOLX |
|---|---|---|
| Price | $16.05 | $76.02 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 10 | 13 |
| Target Price | $19.66 | ★ $77.89 |
| AVG Volume (30 Days) | 3.0M | ★ 95.4M |
| Earning Date | 05-28-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.79 |
| Revenue | N/A | ★ $4,100,500,000.00 |
| Revenue This Year | $18.98 | $4.74 |
| Revenue Next Year | $22.72 | $5.03 |
| P/E Ratio | ★ $29.50 | $96.23 |
| Revenue Growth | N/A | ★ 1.74 |
| 52 Week Low | $15.71 | $53.62 |
| 52 Week High | $32.03 | $76.07 |
| Indicator | LI | HOLX |
|---|---|---|
| Relative Strength Index (RSI) | 34.77 | 69.09 |
| Support Level | N/A | $75.10 |
| Resistance Level | $19.04 | N/A |
| Average True Range (ATR) | 0.49 | 0.19 |
| MACD | -0.17 | 0.03 |
| Stochastic Oscillator | 4.71 | 95.19 |
Li Auto is a leading Chinese NEV manufacturer that designs, develops, manufactures, and sells premium smart NEVs. The company started volume production of its first model Li One in November 2019. The model is a six-seater, large, premium plug-in electric SUV equipped with a range extension system and advanced smart vehicle solutions. It sold over 400,000 NEVs in 2025, accounting for about 3% of China's passenger new energy vehicle market. Beyond Li One, the company expands its product line, including both BEVs and PHEVs, to target a broader consumer base.
Hologic manufactures proprietary products for the healthcare needs of women. The company operates in four segments: diagnostics (44% of total sales), breast health (38%), surgical (16%), and skeletal health (2%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.